POLYPEPTIDE GROUP AG

Pharmaceuticals, Biotechnology and Life Sciences

Targets set1.5°C

SBTI ID

40009124

Informations générales

Localisation

Switzerland

Europe

Secteur d'activité

Pharmaceuticals, Biotechnology and Life Sciences

Type d'organisation

Corporate

Dernière mise à jour

18/09/2025

Objectifs à court terme (Near-Term)
Engagement de réduction des émissions à horizon 2033

Statut

Targets set

Classification

1.5°C

Année cible

2033

Progression vers l'objectif61%
2015 (année de référence)2033
Description complète des objectifs

Near-Term Targets: POLYPEPTIDE GROUP AG commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by 2030 from a 2023 base year. POLYPEPTIDE GROUP AG also commits to increase active annual sourcing of renewable electricity from 54.0% in 2023 to 100% by 2029 and to continue active annual sourcing of 100% renewable electricity through 2030. POLYPEPTIDE GROUP AG further commits to reduce scope 3 GHG emissions from purchased goods and services, capital goods, fuel- and energy-related activities, upstream transportation and distribution and waste generated in operations 61.1% per EUR value added by 2033 from a 2022 base year. Furthermore, POLYPEPTIDE GROUP AG commits that 45% of its suppliers by spend covering purchased goods and services, will have science-based targets by 2029.

Classification détaillée

The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C

Identifiants

ISIN

CH1110760852

LEI

5067007JCKTPOX4G9758

Source : Science Based Targets initiative | Données publiques